Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 246 participants.
Also called NCT06813911
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 246 participants
- Sponsor
- Registry
-
NCT06813911
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, China, France, Germany, Hong Kong SAR China, Italy, Netherlands, Puerto Rico, Spain, Taiwan, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06813911. Randomized; double masking; primary purpose treatment. Start 2025-04-30 (actual); primary completion 2028-02-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
- Acronym
- ADD-VANTAGE
- Condition
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Intervention (Drug)
- Pelacarsen
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Inclisiran
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct06813911- Content hash
41f9a25dc591cbd30f5d930f81e17b64a531ad12fe660f5488cff40484705e62